Domantas Rainys1,2, Adas Cepas1,2, Karolina Dambrauskaite2, Irena Nedzelskiene3, Rytis Rimdeika1,2. 1. Hospital of Lithuanian University of Health Sciences Kauno Klinikos Plastic and Reconstructive Surgery Department, Eivenių str. 2, LT 50009 Kaunas, Lithuania. 2. Lithuanian University of Health Sciences, Medical Faculty, A. Mickevičiaus str. 9, LT 44307 Kaunas, Lithuania. 3. Lithuanian University of Health Sciences, Odontology faculty, Department of Dental and Oral Diseases, Senior Statistician, Eivenių str. 2, LT 50009 Kaunas, Lithuania.
Abstract
OBJECTIVE: Regenerative medicine products such as autologous platelet-rich plasma (autologous PRP) gel may speed up the process of healing. Clinical studies show promising results in the treatment of diabetic foot ulcers (DFUs), however there is lack of scientific evidence of autologous PRP effectiveness in treating leg ulcers of other aetiology. This study evaluates the effectiveness of autologous PRP gel in the treatment of hard-to-heal leg ulcers compared with existing conventional treatment. METHOD: A prospective, randomised controlled, open-labelled clinical trial was carried out between 2014 and 2018. An eight-week study protocol was chosen or until 100% wound re-epithelialisation was observed. Wound size reduction, granulation tissue formation, microbiological wound bed changes and safety were evaluated. RESULTS: A total of 69 patients (35 in the autologous PRP group and 34 in the control group) were included in the study; 25.71% of the autologous PRP group and 17.64% of control group had ulcers completely re-epithelialised (p>0.05). Wound size reduction in the autologous PRP group was 52.35% and 33.36% in the control group (p=0.003). The autologous PRP group showed superiority over conventional treatment in wound bed coverage with granulation (p=0.001). However, more frequent wound contamination was observed at the end of treatment in the autologous PRP group (p=0.024). No severe adverse events were noted during the study. Both treatment methods were considered equally safe. CONCLUSION: Topical application of autologous PRP gel in leg ulcers of various aetiology show beneficial results in wound size reduction and induces the granulation tissue formation. However, it is associated with more frequent microbiological wound contamination.
OBJECTIVE: Regenerative medicine products such as autologous platelet-rich plasma (autologous PRP) gel may speed up the process of healing. Clinical studies show promising results in the treatment of diabetic foot ulcers (DFUs), however there is lack of scientific evidence of autologous PRP effectiveness in treating leg ulcers of other aetiology. This study evaluates the effectiveness of autologous PRP gel in the treatment of hard-to-heal leg ulcers compared with existing conventional treatment. METHOD: A prospective, randomised controlled, open-labelled clinical trial was carried out between 2014 and 2018. An eight-week study protocol was chosen or until 100% wound re-epithelialisation was observed. Wound size reduction, granulation tissue formation, microbiological wound bed changes and safety were evaluated. RESULTS: A total of 69 patients (35 in the autologous PRP group and 34 in the control group) were included in the study; 25.71% of the autologous PRP group and 17.64% of control group had ulcers completely re-epithelialised (p>0.05). Wound size reduction in the autologous PRP group was 52.35% and 33.36% in the control group (p=0.003). The autologous PRP group showed superiority over conventional treatment in wound bed coverage with granulation (p=0.001). However, more frequent wound contamination was observed at the end of treatment in the autologous PRP group (p=0.024). No severe adverse events were noted during the study. Both treatment methods were considered equally safe. CONCLUSION: Topical application of autologous PRP gel in leg ulcers of various aetiology show beneficial results in wound size reduction and induces the granulation tissue formation. However, it is associated with more frequent microbiological wound contamination.
Authors: Sophie K Hasiba-Pappas; Alexandru Cristian Tuca; Hanna Luze; Sebastian P Nischwitz; Robert Zrim; Judith C J Geißler; David Benjamin Lumenta; Lars-P Kamolz; Raimund Winter Journal: Transfus Med Hemother Date: 2022-05-02 Impact factor: 4.040
Authors: Vincenzo Davide Palumbo; Stefano Rizzuto; Giuseppe Damiano; Salvatore Fazzotta; Andrea Gottardo; Giuseppina Mazzola; Attilio Ignazio Lo Monte Journal: J Med Case Rep Date: 2021-02-18